Multimodality review of amyloid-related diseases of the central nervous system

Radiographics

Volumn 36, Issue 4, 2016, Pages 1147-1163

  Miller Thomas, Michelle M ^a   Sipe, Adam L ^a   Benzinger, Tammie L S ^a   McConathy, Jonathan ^a   Connolly, Sarah ^a   Schwetye, Katherine E ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; CENTRAL NERVOUS SYSTEM DISEASE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; MULTIMODAL IMAGING;

AMYLOIDOSIS; CENTRAL NERVOUS SYSTEM DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIMODAL IMAGING;

EID: 84978034103     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.2016150172     Document Type: Review

References (67)

1. Wippold FJ 2nd, Cairns N, Vo K, Holtzman DM, Morris JC. Neuropathology for the neuroradiologist: plaques and tangles. AJNR Am J Neuroradiol 2008;29(1): 18-22.
2. Thal DR, Rüb U, Orantes M, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58(12): 1791-1800.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, Va: American Psychiatric Association, 2013.
4. Alzheimer’s Association. 2014 Alzheimer’s disease facts and figures. Alzheimers Dement 2014;10(2): e47-e92.
5. Murray AD. Imaging approaches for dementia. AJNR Am J Neuroradiol 2012;33(10): 1836-1844.
6. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3): 263-269.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34(7): 939-944.
8. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3): 270-279.
9. Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid b peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 2013;38(1): 6-23.
10. Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 1997;9(suppl 1): S257-S261; discussion S269-S272.
11. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 2011;70(11): 960-969.
12. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367(9): 795-804.
13. O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011;34: 185-204.
14. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996;47(5): 1113-1124.
15. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2012;2(7): a006247.
16. Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of tau protein in aggresomes. J Biol Chem 2012;287(24): 20522-20533.
17. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992;42(3 Pt 1): 631-639.
18. Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2(9): a006221.
19. Tuppo EE, Arias HR. The role of inflammation in Alzheimer’s disease. Int J Biochem Cell Biol 2005;37(2): 289-305.
20. Mott RT, Hulette CM. Neuropathology of Alzheimer’s disease. Neuroimaging Clin N Am 2005;15(4): 755-765, ix.
21. Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol 2014;35(11): 2030-2038.
22. Laakso MP, Soininen H, Partanen K, et al. MRI of the hippocampus in Alzheimer’s disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 1998;19(1): 23-31.
23. Ochs AL, Ross DE, Zannoni MD, Abildskov TJ, Bigler ED; Alzheimer’s disease neuroimaging initiative: comparison of automated brain volume measures obtained with NeuroQuant and FreeSurfer. J Neuroimaging 2015;25(5): 721-727.
24. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64(10): 1704-1711.
25. Liu RS, Lemieux L, Bell GS, et al. A longitudinal study of brain morphometrics using quantitative magnetic resonance imaging and difference image analysis. Neuroimage 2003;20(1): 22-33.
26. den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133(Pt 4): 1163-1172.
27. Barnes J, Bartlett JW, van de Pol LA, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer’s disease. Neurobiol Aging 2009;30(11): 1711-1723.
28. Shi F, Liu B, Zhou Y, Yu C, Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer’s disease: meta-analyses of MRI studies. Hippocampus 2009;19(11): 1055-1064.
29. Brown RK, Bohnen NI, Wong KK, Minoshima S, Frey KA. Brain PET in suspected dementia: patterns of altered FDG metabolism. RadioGraphics 2014;34(3): 684-701.
30. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32(4): 486-510.
31. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69(9): 871-877.
32. McConathy J, Sheline YI. Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry 2015;77(8): 685-692.
33. Rowe CC, Ng S, Ackermann U, et al. Imaging b-amyloid burden in aging and dementia. Neurology 2007;68(20): 1718-1725.
34. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67(3): 446-452.
35. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009;66(12): 1469-1475.
36. 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51(6): 913-920.
37. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 2013;9(1): e1-e16.
38. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 2013;54(3): 476-490.
39. 18F-THK5105 PET. Brain 2014;137(Pt 6): 1762-1771.
40. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34(2): 457-468.
41. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. Tau PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep 2014;14(11): 500.
42. James OG, Doraiswamy PM, Borges-Neto S. PET imaging of tau pathology in Alzheimer’s disease and tauopathies. Front Neurol 2015;6: 38.
43. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer’s disease. Nature 2009;461(7266): 916-922.
44. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH, Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30(5): 637-649.
45. Greenberg SM, Vonsattel JP, Stakes JW, Gruber M, Finklestein SP. The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993;43(10): 2073-2079.
46. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry 2012;83(2): 124-137.
47. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001;56(4): 537-539.
48. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral b-amyloid angiopathies: hereditary and sporadic. Brain Pathol 2006;16(1): 30-39.
49. Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol 2009;9: 3.
50. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology 2000;20(1): 8-22.
51. Chao CP, Kotsenas AL, Broderick DF. Cerebral amyloid angiopathy: CT and MR imaging findings. RadioGraphics 2006;26(5): 1517-1531.
52. Haacke EM, DelProposto ZS, Chaturvedi S, et al. Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging. AJNR Am J Neuroradiol 2007;28(2): 316-317.
53. Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010;74(17): 1346-1350.
54. Linn J, Herms J, Dichgans M, et al. Subarachnoid hemosiderosis and superficial cortical hemosiderosis in cerebral amyloid angiopathy. AJNR Am J Neuroradiol 2008;29(1): 184-186.
55. Castro Caldas A, Silva C, Albuquerque L, Pimentel J, Silva V, Ferro JM. Cerebral amyloid angiopathy associated with inflammation: report of 3 cases and systematic review. J Stroke Cerebrovasc Dis 2015;24(9): 2039-2048.
56. Kotsenas AL, Morris JM, Wald JT, Parisi JE, Campeau NG. Tumefactive cerebral amyloid angiopathy mimicking CNS neoplasm. AJR Am J Roentgenol 2013;200(1): 50-56.
57. Nouh A, Borys E, Gierut AK, Biller J. Amyloid-beta related angiitis of the central nervous system: case report and topic review. Front Neurol 2014;5: 13.
58. Salvarani C, Hunder GG, Morris JM, Brown RD Jr, Christianson T, Giannini C. Aβ-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis. Neurology 2013;81(18): 1596-1603.
59. Scolding NJ, Joseph F, Kirby PA, et al. Aβ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005;128(Pt 3): 500-515.
60. Martucci M, Sarria S, Toledo M, et al. Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical outcome. Neuroradiology 2014;56(4): 283-289.
61. Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry 2011;82(1): 20-26.
62. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004;55(2): 250-256.
63. Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007;68(17): 1411-1416.
64. Landau D, Avgeropoulos N, Ma J. Cerebral amyloidoma mimicking intracranial tumor: a case report. J Med Case Reports 2010;4: 308.
65. Fischer B, Palkovic S, Rickert C, Weckesser M, Wassmann H. Cerebral AL lambda-amyloidoma: clinical and pathomorphological characteristics-review of the literature and of a patient. Amyloid 2007;14(1): 11-19.
66. Gandhi D, Wee R, Goyal M. CT and MR imaging of intracerebral amyloidoma: case report and review of the literature. AJNR Am J Neuroradiol 2003;24(3): 519-522.
67. Lee J, Krol G, Rosenblum M. Primary amyloidoma of the brain: CT and MR presentation. AJNR Am J Neuroradiol 1995;16(4): 712-714.